Umar Murad, MD
Family Medicine · Chavies, KYNPI 1952391724
Payments from drug & device makers
Across 115 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$432
- Lilly USA, LLC$315
- Corium, LLC$153
- Collegium Pharmaceutical, Inc.$110
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108
- AbbVie$93
- plus $789 from 20 others
What the payments were for
- Food & beverage$1,98799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $432 |
| Lilly USA, LLC | 17 | $315 |
| Corium, LLC | 9 | $153 |
| Collegium Pharmaceutical, Inc. | 6 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $108 |
| AbbVie(2 entities) | 7 | $93 |
| Amgen | 4 | $73 |
| Boehringer Ingelheim | 3 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $63 |
| Novo Nordisk | 2 | $61 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| AstraZeneca | 3 | $53 |
| Ironshore Pharmaceuticals Inc. | 3 | $48 |
| GSK | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 1 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Bayer | 2 | $36 |
| Pfizer | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Inogen, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $11 |
How this compares
$1,999 in reported general payments places this provider in the 65th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 143 | $175,751 |
| MounjaroTirzepatide | 124 | $131,841 |
| EliquisApixaban | 89 | $76,889 |
| OzempicSemaglutide | 68 | $66,015 |
| EntrestoSacubitril/Valsartan | 59 | $55,681 |
| FarxigaDapagliflozin Propanediol | 51 | $34,319 |
| JanuviaSitagliptin Phosphate | 32 | $21,976 |
| XareltoRivaroxaban | 18 | $19,341 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $19,296 |
| JardianceEmpagliflozin | 25 | $19,216 |
| TrintellixVortioxetine Hydrobromide | 39 | $17,925 |
| LinzessLinaclotide | 26 | $15,659 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $15,575 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 811 | $14,172 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $315 | $307,592267 claims |
| PfizerEliquis | $29 | $76,88989 claims |
| Novo NordiskOzempic | $61 | $66,01568 claims |
| NovartisEntresto | $432 | $55,68159 claims |
| AstraZenecaFarxiga, Brilinta | $53 | $39,07363 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $63 | $34,79246 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $48 | $22,73839 claims |
| MerckJanuvia | $18 | $21,97632 claims |
| AbbVieLinzess | $93 | $15,65926 claims |
| Esperion Therapeutics, Inc.Nexlizet | $54 | $10,57319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Chavies
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.